As at 7 October 2019, Cello's issued share capital comprises 106,587,917 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 106,134,917 Ordinary Shares.
The above figure (106,134,917 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Cello Health plc
020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Group Finance Director
Cenkos Securities plc
020 7397 8900
020 7466 5000
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too.
The group delivered net revenue of £54.5mln for the first six months of the year,...